ArticleHealth science reports2025
CD40LG as a Biomarker in Rheumatoid Arthritis: Links to Bone Destruction and Interstitial Lung Disease - A Bioinformatic Analysis With Clinical Validation.
Article in Health science reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background and Aims: Biomarkers are essential tools in the diagnosis and management of various diseases. Rheumatoid arthritis (RA) is a systemic inflammatory disorder that frequently results in damage to joints and organs. Here, we examined potential biomarkers and therapeutic agents for RA patients. Methods: Three microarray datasets and clinical data for synovial tissue were sourced from the publicly available Gene Expression Omnibus (GEO) database. Differentially expressed genes (DEGs) in RA versus osteoarthritis (OA) patients were identified, followed by functional enrichment analysis, gene set enrichment analysis (GSEA), and protein-protein interaction (PPI) network analysis to explore DEG-associated pathways and identify hub genes. Furthermore, serum levels of relevant antibodies were measured using enzyme-linked immunosorbent assay (ELISA). Additionally, potential therapeutic compounds for RA were predicted using the Connectivity Map (CMap) database, and molecular docking was conducted to assess their binding affinities with target proteins. Results: A total of 409 DEGs were identified, with Gene Ontology (GO), Kyoto Encyclopedia of Genes and Genomes (KEGG), and GSEA analyses highlighting enrichment in cytokine activity, cytokine-receptor interactions, and the primary immunodeficiency pathway. Five key modules and hub genes were found using Cytoscape, and expression levels of CD40LG, ITGAX, and PTPRC were validated with another GEO data set. ELISA confirmed elevated serum CD40LG antibody levels in RA patients, suggesting its potential as a biomarker, especially in those with interstitial lung disease (ILD) or bone destruction. Connectivity map analysis identified small molecules that may reverse DEGs, and molecular docking showed emetine, oligomycin, cromoglicic acid, sulfinpyrazone, buspirone, and chlorogenic acid had favorable binding energies. Conclusion: CD40LG is a potential biomarker for RA, especially in patients with ILD or bone damage. Emetine, oligomycin, cromoglicic acid, sulfinpyrazone, buspirone, and chlorogenic acid are potential therapeutic agents for RA treatments.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.